As another cannabis earnings season comes to a close, the financial results from some of the smaller U.S. multi-state operators (MSOs) have fallen under the radar, despite posting awe-inspiring numbers.... read more →
While there have been glimmers of an upturn recently in the cannabis industry, the drama of the business of selling a federally illegal cash crop continues. And there is little... read more →
The AlphaMind Acquisition is a Milestone Moment for the Rapidly Ascending Cannabis Company With the Transformational Deal Now Complete, Hollister Has Officially Diversified into the Flourishing World of Psychedelics Hollister... read more →
Hollister Biosciences, One of the Hottest Names in Cannabis, is Moving Forward with Another Blockbuster Deal Following its Recent Acquisition of Venom Extracts Hollister Announced That it Reached a Definitive... read more →
Carl Saling, CEO of Hollister Biosciences (CSE: HOLL) (OTC: HSTRF) (FRA: HOB) and Venom Extracts CEO Mason Cave sat down with TCI host Alyssa Boston (Miss Universe Canada 2019 +... read more →
Hollister Biosciences is on a Roll, and the Investing Community is Finally Giving the Company the Attention it Rightfully Deserves Since Bottoming at the Start of April, HOLL Stock Has... read more →
The Highly Accretive Acquisition Strengthens Hollister's Brand Portfolio While Expanding its Footprint Across Multiple U.S. States Venom Extracts Brings With it 2019 EBITDA of $2.5 Million on Revenue of $16.4... read more →
Hollister Biosciences Signs LOI to Acquire Legal Medicinal Mushroom and Psilocybin Firm Alphamind Brands Alphamind is Developing Mushroom Products and Conducting R&D for Psilocybin Pharmaceutical Applications Hollister Biosciences (CSE: HOLL)... read more →
